These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Topographically designed analogues of [D-Pen,D-Pen5]enkephalin. Hruby VJ; Toth G; Gehrig CA; Kao LF; Knapp R; Lui GK; Yamamura HI; Kramer TH; Davis P; Burks TF J Med Chem; 1991 Jun; 34(6):1823-30. PubMed ID: 1648137 [TBL] [Abstract][Full Text] [Related]
4. Assessment of stereoselectivity of trimethylphenylalanine analogues of delta-opioid [D-Pen(2),D-Pen(5)]-enkephalin. Witt KA; Slate CA; Egleton RD; Huber JD; Yamamura HI; Hruby VJ; Davis TP J Neurochem; 2000 Jul; 75(1):424-35. PubMed ID: 10854288 [TBL] [Abstract][Full Text] [Related]
5. Opioid peptides: simultaneous delta agonism and mu antagonism in somatostatin analogues. Bonner GG; Davis P; Stropova D; Ferguson R; Yamamura HI; Porreca F; Hruby VJ Peptides; 1997; 18(1):93-100. PubMed ID: 9114458 [TBL] [Abstract][Full Text] [Related]
6. Evolution of the Dmt-Tic pharmacophore: N-terminal methylated derivatives with extraordinary delta opioid antagonist activity. Salvadori S; Balboni G; Guerrini R; Tomatis R; Bianchi C; Bryant SD; Cooper PS; Lazarus LH J Med Chem; 1997 Sep; 40(19):3100-8. PubMed ID: 9301674 [TBL] [Abstract][Full Text] [Related]
7. Side chain methyl substitution in the delta-opioid receptor antagonist TIPP has an important effect on the activity profile. Tourwé D; Mannekens E; Diem TN; Verheyden P; Jaspers H; Tóth G; Péter A; Kertész I; Török G; Chung NN; Schiller PW J Med Chem; 1998 Dec; 41(26):5167-76. PubMed ID: 9857087 [TBL] [Abstract][Full Text] [Related]
8. Unexpected antinociceptive potency of cyclic [D-Tca1]CTAP: potential for a novel mechanism of action. Horan PJ; Wild KD; Kazmierski WM; Ferguson R; Hruby VJ; Weber SJ; Davis TP; Fang L; Knapp RJ; Yamamura HI Eur J Pharmacol; 1993 Mar; 233(1):53-62. PubMed ID: 8386089 [TBL] [Abstract][Full Text] [Related]
10. Development of a model for the delta opioid receptor pharmacophore. 2. Conformationally restricted Phe3 replacements in the cyclic delta receptor selective tetrapeptide Tyr-c[D-Cys-Phe-D-Pen]OH (JOM-13). Mosberg HI; Omnaas JR; Lomize A; Heyl DL; Nordan I; Mousigian C; Davis P; Porreca F J Med Chem; 1994 Dec; 37(25):4384-91. PubMed ID: 7996550 [TBL] [Abstract][Full Text] [Related]
11. Synthesis, opioid receptor binding, and bioassay of naltrindole analogues substituted in the indolic benzene moiety. Ananthan S; Johnson CA; Carter RL; Clayton SD; Rice KC; Xu H; Davis P; Porreca F; Rothman RB J Med Chem; 1998 Jul; 41(15):2872-81. PubMed ID: 9667975 [TBL] [Abstract][Full Text] [Related]
12. Structure-activity relationships of dermorphin analogues containing N-substituted amino acids in the 2-position of the peptide sequence. Schmidt R; Kálmán A; Chung NN; Lemieux C; Horváth C; Schiller PW Int J Pept Protein Res; 1995 Jul; 46(1):47-55. PubMed ID: 7558596 [TBL] [Abstract][Full Text] [Related]
13. Direct influence of C-terminally substituted amino acids in the Dmt-Tic pharmacophore on delta-opioid receptor selectivity and antagonism. Balboni G; Salvadori S; Guerrini R; Negri L; Giannini E; Bryant SD; Jinsmaa Y; Lazarus LH J Med Chem; 2004 Jul; 47(16):4066-71. PubMed ID: 15267245 [TBL] [Abstract][Full Text] [Related]
14. Effect of aromatic amino acid substitutions in the 3-position of cyclic beta-casomorphin analogues on mu-opioid agonist/delta-opioid antagonist properties. Schmidt R; Wilkes BC; Chung NN; Lemieux C; Schiller PW Int J Pept Protein Res; 1996 Nov; 48(5):411-9. PubMed ID: 8956074 [TBL] [Abstract][Full Text] [Related]
15. Novel ligands lacking a positive charge for the delta- and mu-opioid receptors. Schiller PW; Berezowska I; Nguyen TM; Schmidt R; Lemieux C; Chung NN; Falcone-Hindley ML; Yao W; Liu J; Iwama S; Smith AB; Hirschmann R J Med Chem; 2000 Feb; 43(4):551-9. PubMed ID: 10691681 [TBL] [Abstract][Full Text] [Related]
16. Synthesis and biological properties of beta-MePhe3 analogues of deltorphin I and dermenkephalin: influence of biased chi 1 Phe3 residues on peptide recognition for delta-opioid receptors. Misicka A; Cavagnero S; Horvath R; Davis P; Porreca F; Yamamura HI; Hruby VJ J Pept Res; 1997 Jul; 50(1):48-54. PubMed ID: 9273887 [TBL] [Abstract][Full Text] [Related]
17. Potent Dmt-Tic pharmacophoric delta- and mu-opioid receptor antagonists. Li T; Fujita Y; Shiotani K; Miyazaki A; Tsuda Y; Ambo A; Sasaki Y; Jinsmaa Y; Marczak E; Bryant SD; Salvadori S; Lazarus LH; Okada Y J Med Chem; 2005 Dec; 48(25):8035-44. PubMed ID: 16335927 [TBL] [Abstract][Full Text] [Related]
18. Conversion of delta-, kappa- and mu-receptor selective opioid peptide agonists into delta-, kappa- and mu-selective antagonists. Schiller PW; Weltrowska G; Nguyen TM; Lemieux C; Chung NN; Lu Y Life Sci; 2003 Jun; 73(6):691-8. PubMed ID: 12801590 [TBL] [Abstract][Full Text] [Related]
19. Potency differences for D-Phe-Cys-Tyr-D-Trp-Arg-Thr-Pen-Thr-NH2 as an antagonist of peptide and alkaloid micro-agonists in an antinociception assay. Sterious SN; Walker EA J Pharmacol Exp Ther; 2003 Jan; 304(1):301-9. PubMed ID: 12490605 [TBL] [Abstract][Full Text] [Related]
20. A novel cyclic enkephalin analogue with potent opioid antagonist activity. Weltrowska G; Lu Y; Lemieux C; Chung NN; Schiller PW Bioorg Med Chem Lett; 2004 Sep; 14(18):4731-3. PubMed ID: 15324897 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]